Current management options for latent tuberculosis: A review

Brianna L. Norton, David P. Holland

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve comple- tion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens.

Original languageEnglish (US)
Pages (from-to)163-173
Number of pages11
JournalInfection and Drug Resistance
Issue number1
StatePublished - 2012
Externally publishedYes


  • Interferon-gamma release assay
  • Isoniazid
  • Rifampin
  • Rifapentine
  • Tuberculin skin test

ASJC Scopus subject areas

  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Current management options for latent tuberculosis: A review'. Together they form a unique fingerprint.

Cite this